Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015

Vaccine

Volumn 34, Issue 26, 2016, Pages 2865-2869

  Giersing, Birgitte K ^a   Modjarrad, Kayvon ^b   Kaslow, David C ^c   Moorthy, Vasee S ^a   Bavdekar, Ashish ^d   Cichutek, Klaus ^e   Cravioto, Alejandro ^f   Fritzell, Bernard ^g   Graham, Barney ^h   Karron, Ruth ⁱ   Lanata, Claudio ^j,k   Powell, Mair ^l   Shao, Yiming ^m   Smith, Peter ⁿ  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c PATH   (United States)

^d KEM HOSPITAL   (India)

^e PAUL EHRLICH INSTITUT   (Germany)

^f Global Eval uative Sciences Inc   (United States)

^g National Institutes of Health ^*  (France)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^j INSTITUTO DE INVESTIGACIÓN NUTRICIONAL   (Peru)

^k California   (Peru)

^l MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^m CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

ⁿ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Candidate; LMIC; PPC; Product development; Vaccine

Indexed keywords

VACCINE;

ADVISORY COMMITTEE; ARTICLE; CONSULTATION; DENGUE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNIZATION; INCOME; INFECTION; INFLUENZA; INVESTMENT; MALARIA; NOROVIRUS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PUBLIC HEALTH; STREPTOCOCCUS GROUP A; WORLD HEALTH ORGANIZATION; COMMUNICABLE DISEASE CONTROL; GLOBAL HEALTH; MEDICAL RESEARCH; SWITZERLAND; TRENDS; VACCINATION;

ADVISORY COMMITTEES; BIOMEDICAL RESEARCH; COMMUNICABLE DISEASE CONTROL; GLOBAL HEALTH; HUMANS; SWITZERLAND; VACCINATION; VACCINES; WORLD HEALTH ORGANIZATION;

EID: 84969922928     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.078     Document Type: Article

References (19)

1. http://www.niaid.nih.gov/topics/vaccines/Documents/JordanReport2012.pdf.
2. http://www.who.int/immunization/research/meetings_workshops/pdvac/en/.
3. http://apps.who.int/immunization/research/target-product-profile/WHO_Ebola_vaccine_TPP_version_final.pdf?ua=1.
4. Modjarrad K., Giersing B., Kaslow D.C., Smith P.G., Moorthy V.S. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine 2015, WHO RSV Vaccine Consultation Expert Group, pii: S0264-410X(15)00767-7.
5. http://ir.novavax.com/phoenix.zhtml?c=71178%26p=irol-newsArticle%26ID=2091286.
6. Kotloff K.L., Nataro J.P., Blackwelder W.C., Nasrin D., Farag T.H., Panchalingam S., et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013, 382(9888):209-222.
7. Platts-Mills J.A., Babji S., Bodhidatta L., Gratz J., Haque R., Havt A., et al. Pathogen-specific burdens of community diarrhoea in developing countries: a multisite birth cohort study (MAL-ED). Lancet Glob Health 2015, 3(September (9)):e564-e575.
8. Lundgren A., Bourgeois L., Carlin N., Clements J., Gustafsson B., Hartford M., et al. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. Vaccine 2014, 32(52):7077-7084.
9. Darsley M.J., Chakraborty S., DeNearing B., Sack D.A., Feller A., Buchwaldt C., et al. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 2012, 19(12):1921-1931.
10. http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/.
11. http://apps.who.int/iris/bitstream/10665/149822/1/WHO_IVB_14.09_eng.pdf.
12. Hadinegoro S.R., Arredondo-García J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, 373(13):1195-1206.
13. Rid A., Saxena A., Baqui A.H., Bhan A., Bines J., Bouesseau M.C., et al. Placebo use in vaccine trials: recommendations of a WHO expert panel. Vaccine 2014, 32(37):4708-4712.
14. http://apps.who.int/iris/bitstream/10665/69063/1/WHO_FCH_CAH_05.07.pdf.
15. Belshe R.B., Leone P.A., Bernstein D.I., Wald A., Levin M.J., Stapleton J.T., et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012, 366:34-43.
16. Looker K.J., Magaret A.S., Turner K.M., Vickerman P., Gottlieb S.L., Newman L.M., et al. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLOS ONE 2015, 10(1):e114989.
17. Looker K.J., Magaret A.S., May M.T., Turner K.M., Vickerman P., Gottlieb S.L., et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLOS ONE 2015, 10(10):e0140765.
18. Zeng M., Mao X.H., Li J.X., Tong W.D., Wang B., Zhang Y.J., et al. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015, 386(10002):1457-1464.
19. Liang Z., Wang J. EV71 vaccine, an invaluable gift for children. Clin Transl Immunol 2014, 3(10):e28.